This year’s release of the OnCore Clinical and Translational Research Software, Version 10.0, incorporates work done in eight collaborative projects with research organizations across the country.
“What we’re especially excited about with this version is bringing together the work that has been going on in several collaborative initiatives and making it available to all the OnCore centers,"said Anthony O’Hare, PhD, Chief Scientific Officer at PercipEnz Technologies, Inc., creators of OnCore.
Version 10.0 includes functionality that was previously only available to research centers who were participating in specific collaborative initiatives. New functionality in OnCore includes support for multi-center trials, a new Affiliate Network Administration portal, enhanced communication and reporting tools, and additions to the OnCore Software Developers Toolkit (SDK) for integration with other systems such as those for electronic IRB management.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.